Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort

Journal of Neuro-Oncology

Volumn 120, Issue 2, 2014, Pages 431-440

  Odia, Yazmin ^a   Shih, Joanna H ^b   Kreisl, Teri N ^b   Fine, Howard A ^c  

^a NEUROLOGICAL INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Glioblastoma; Glioma; Toxicity

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; ENZASTAURIN; TANDUTINIB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ANTIANGIOGENIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BONE NECROSIS; BRAIN ISCHEMIA; CANCER RECURRENCE; CANCER SUSCEPTIBILITY; COHORT ANALYSIS; COLON PERFORATION; CONTROLLED STUDY; DEATH; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; EPISTAXIS; FATIGUE; FEMALE; GLIOBLASTOMA; HAND FOOT SYNDROME; HEADACHE; HOARSENESS; HUMAN; HYPERNATREMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LIQUORRHEA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MYALGIA; NATIONAL HEALTH ORGANIZATION; NAUSEA; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROTEINURIA; RASH; RETINOPATHY; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; UREMIA; WOUND COMPLICATION; WOUND INFECTION; AGED; CANCER GRADING; CHEMICALLY INDUCED; FOLLOW UP; GLIOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE II AS TOPIC; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; HYPERTENSION; HYPOPHOSPHATEMIA; MALE; MIDDLE AGED; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASM GRADING; PROGNOSIS; PROTEINURIA; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84910111103     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1571-6     Document Type: Article

References (42)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology 14(Suppl 5):v1–v49
2. Louis D, Ohgaki H, Wiestler O et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109
3. Frankel SA, German WJ (1958) Glioblastoma multiforme. J Neurosurg 15(5):489–503
4. Pichlmeier U, Bink A, Schackert G, Stummer W (2008) Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro-Oncology 10(6):1025–1034
5. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572
6. Laperriere N, Zuraw L, Cairncross G (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64(3):259–273
7. Scott CB, Scarantino C, Urtasun R et al (1998) Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40(1):51–55
8. Tsao MN, Mehta MP, Whelan TJ et al (2005) The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 63(1):47–55
9. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
10. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507
11. Maxwell M, Naber SP, Wolfe HJ et al (1991) Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression. Cancer Res 51(4):1345–1351
12. Millauer B, Shawver LK, Plate KH, Risaui W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367(6463):576–579
13. Stefanik DF, Fellows WK, Rizkalla LR et al (2001) Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J Neurooncol 55(2):91–100
14. Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359(6398):845–848
15. Presta LG, Chen H, O’Connor SJ et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593–4599
16. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23(16):3706–3712
17. Kerr C (2005) Bevacizumab and chemotherapy improves survival in NSCLC. Lancet Oncol 6(5):266
18. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111
19. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729
20. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745
21. Kreisl TN, Zhang W, Odia Y et al (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-Oncology 13(10):1143–1150
22. Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8):465–477
23. Gressett SM, Shah SR (2009) Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43(3):490–501
24. Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM (2010) Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncol 15(2):130–141
25. Chinot OL, de La Motte Rouge T, Moore N et al (2011) AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28(4):334–340
26. Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722
27. Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708
28. Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S (2013) The impact of bevacizumab (Avastin) on survival in metastatic solid tumors—a meta-analysis and systematic review. PLoS ONE 8(1):e51780
29. Elice F, Rodeghiero F, Falanga A, Rickles FR (2009) Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 22(1):115–128
30. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncol 13(10):1084–1096
31. Laskin J, Crinò L, Felip E et al (2012) Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol 7(1):203–211. doi:10.1097/JTO.0b013e3182370e02
32. Peters K, Coyle T, Vredenburgh J, Desjardins A, Friedman H, Reardon D (2011) Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. J Neurooncol 101(1):155–159
33. Ricciardi S, Tomao S, de Marinis F (2009) Toxicity of targeted therapy in non–small-cell lung cancer management. Clin Lung Cancer 10(1):28–35
34. Schuster C, Eikesdal HP, Puntervoll H et al (2012) Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS ONE 7(6):e38364
35. Shepard DR, Garcia JA (2009) Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 9(6):795–805
36. Thomssen C, Pierga JY, Pritchard KI et al (2012) First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology 82(4):218–227
37. Girardi F, Franceschi E, Brandes AA (2010) Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncol 15(7):683–694
38. Fraum T, Kreisl T, Sul J, Fine H, Iwamoto F (2011) Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol 105(2):281–289
39. Wheeler H, Black J, Webb S, Shen H (2012) Dehiscence of corticosteroid-induced abdominal striae in a 14-year-old boy treated with bevacizumab for recurrent glioblastoma. J Child Neurol 27(7):927–929
40. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259
41. Gururangan S, Chi SN, Young Poussaint T et al (2010) Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J Clin Oncol 28(18):3069–3075
42. Liu AK, Macy ME, Foreman NK (2009) Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 75(4):1148–1154